SCHEMBL12220501

SCHEMBL12220501

CC(=O)/C=C/c1ccc(O)c(C)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 3/20 0.73
PTGS1 P23219 1/20 0.73
BACE1 P56817 2/20 0.64
APP P05067 3/20 0.63
TTR P02766 3/20 0.50
KDM4E B2RXH2 2/20 0.50
GLA P06280 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
DPP4 P27487 2/20 0.50
ALOX5 P09917 2/20 0.50
NFKB1 P19838 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
MMP1 P03956 2/20 0.50
MMP2 P08253 2/20 0.50
MMP9 P14780 2/20 0.50
MEN1 O00255 1/20 0.50
HDAC3 O15379 1/20 0.50
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15481424 0.87 BACE1 (0.66) IAPPPTGS1BACE1APPTTR
SCHEMBL471934 0.85 KDM4E (0.70) IAPPPTGS1BACE1APPTTR
SCHEMBL21986902 0.85 IAPP (0.73) IAPPPTGS1BACE1APPTTR
SCHEMBL21986720 0.85 IAPP (0.73) IAPPPTGS1BACE1APPTTR
SCHEMBL471935 0.85 KDM4E (0.70) IAPPPTGS1BACE1APPTTR
SCHEMBL1881134 0.85 IAPP (1.00) IAPPPTGS1BACE1APPTTR
SCHEMBL1881133 0.85 IAPP (1.00) IAPPPTGS1BACE1APPTTR
SCHEMBL29364807 0.85 IAPP (1.00) IAPPPTGS1BACE1APPTTR
SCHEMBL14926717 0.85 IAPP (0.61) IAPPPTGS1BACE1APPKDM4E
SCHEMBL8965107 0.84 BACE1 (0.88) IAPPPTGS1BACE1APPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20180086703-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2018-03-29 US disclosed
US-20180002306-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE CHROMOCELL CORP (US) 2018-01-04 US disclosed
US-9796672-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2017-10-24 US disclosed
US-20170144970-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-05-25 US disclosed
EP-1567143-B1 ANTHRANILIC ACID AMIDES AND THE DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL AGENTS SYMRISE AG (DE) 2013-08-14 EP disclosed
US-8497361-B2 Topoisomerase binding probe and method of use SRI INTERNATIONAL (US) 2013-07-30 US disclosed
US-20110256115-A1 HYDROSOLUBLE [6)O-ALPHA-D-GLCP-(1->]N-6-O-BETA-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS LIBRAGEN (FR) 2011-10-20 US disclosed
WO-2008003978-A2 DIOXO-ALKANES AND DIOXO-ALKENES PHYTOPHARM PLC (GB) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110256115-A1 HYDROSOLUBLE [6)O-ALPHA-D-GLCP-(1->]N-6-O-BETA-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS UGGT1, UGDH, CYP24A1 IAPP 438/4885PTGS1 771/4885BACE1 645/4885
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease TMEM97, SLC18A2, PSD IAPP 441/4885PTGS1 2452/4885BACE1 50/4885
US-20180002306-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE TAS2R10, TAS2R40, TAS2R5 IAPP 41/4885PTGS1 2090/4885BACE1 4134/4885
US-20180086703-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, PSD IAPP 441/4885PTGS1 2452/4885BACE1 50/4885
US-20170144970-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, PSD IAPP 441/4885PTGS1 2452/4885BACE1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.